Additional Financial Provisions Clause Samples
Additional Financial Provisions. The financial provisions set forth in Article 8 of the Agreement applicable to Oncology Products (including but not limited to Section 8.6 and Section 8.8) will apply to the Amendment-Additional Collaboration Target Products in the same manner as applied to each Oncology Product except that:
a. Section 8.1(iii) of the Agreement shall not apply with respect to the Amendment-Additional Collaboration Target Program, and instead Section 8.1 of the Agreement shall be amended to add that AstraZeneca shall pay Isis an additional up-front fee of $[***] in partial consideration for the Option granted by Isis to AstraZeneca under Section 3.5 for the Amendment-Additional Collaboration Target within 30 days after the Amendment Date;
b. In partial consideration for the Option granted by Isis to AstraZeneca under Section 3.5 of the Agreement in respect of the Amendment-Additional Collaboration Target, AstraZeneca will pay Isis $[***] when the Amendment- Additional Collaboration Target Program achieves Target Sanction, such payment to be due within 30 days following receipt of an invoice from Isis following such achievement; and
c. Section 8.2 of the Agreement shall be amended such that up to a total of $[***] may become due and payable thereunder for a total of five Options (if AstraZeneca exercises all of its Options under the Agreement and under this Amendment and if a fourth Oncology Collaboration Program is added under Section 2.2.4 of the Agreement).
Additional Financial Provisions. The financial provisions set forth in Article 8 of the Agreement applicable to Oncology Products (including but not limited to Section 8.6 and Section 8.8) will apply to the Amendment-Additional Collaboration Target Products in the same manner as applied to each Oncology Product except that:
a. Section 8.1(iii) of the Agreement shall not apply with respect to the Amendment-Additional Collaboration Target Program, and instead Section 8.1 of the Agreement shall be amended to add that AstraZeneca shall pay Isis an additional up-front fee of $[***] in partial consideration for the Option granted by ▇▇▇▇ to AstraZeneca under Section 3.5 for the Amendment-Additional Collaboration Target within 30 days after the Amendment Date;
Additional Financial Provisions. 1.1.1 [***].
Additional Financial Provisions. No consecutive quarterly losses allowed. ADDITIONAL PROVISIONS.
Additional Financial Provisions. The following is hereby added as Section 6.14 of the Collaboration Agreement: “In the event that a Licensed Product is Covered by a ▇▇▇▇ ▇▇ Patent Right or a Joint PD Patent Right (each, as defined in the PD Agreement) in a particular country, and such Licensed Product is not Covered by any Penn Patent Rights, Joint Patent Rights, or Licensed Know- How, the royalty and milestone payments under this Agreement shall apply to such Licensed Product as follows:
(a) Solely with respect to such Licensed Product and such country and solely for purposes of subsections (b) and (c) below, the definition of “Program Valid Claim” shall be deemed to refer to such ▇▇▇▇ ▇▇ Patent Rights or Joint PD Patent Rights (each, as defined in the PD Agreement) instead of Penn Patent Rights A or Penn Patent Rights B;
(b) Licensee will pay Penn milestone payments in accordance with the terms of Section
Additional Financial Provisions. Borrower agrees that while this Agreement is in effect, Borrower shall comply with the following: Annual submission of SEC form 10K due within 120 days of each Year end and Quarterly submission of SEC 10Q form due within 60 days of quarter end. Submission of quarterly and year end operating statements for each location within 45 days of period end. Annual projection for the following twelve month period, will be due by January 31, 2001 for the period starling January 1, 2001 hro▇▇▇ ▇▇▇▇mber 31, 2001. Quarterly Mystery Shopping Report due within 45 days of quarter end.
Additional Financial Provisions